Revisiting Intracavitary Immunotherapy of Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35247905.
- Also identified by DOI 10.1158/1078-0432.CCR-22-0201.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ovarian cancer is often limited to the peritoneal cavity in the form of peritoneal carcinomatosis. Peritoneal spreading offers the opportunity for locoregional delivery of combinations of immunotherapy agents, maximizing bioavailability while potentially reducing systemic exposure and side effects. See related article by Orr et al., p. 2038.
Medical subject headings
- Ovarian Neoplasms
- Peritoneal Neoplasms